Page 7 - Phase 3 News Today

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

Relmada Therapeutics, Inc. (RLMD) saw a 6% increase in share value on Monday. This was due to the announcement of efficacy and safety results from their Phase 3 study (Study REL-1017-310) of REL-1017 in patients with Major Depressive Disorder (MDD).

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.

Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.

NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology...

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025

Shares of Vistagen Therapeutics, Inc. (VTGN) rose by 713% on Monday due to the company's announcement of positive topline results from the Phase 3 PALISADE-2 trial.

Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.